• 1
    UNAIDS. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO): AIDS epidemic update 2007. Available at accessed 1 March 2009..
  • 2
    Mathers BM, Degenhardt L, Phillips B et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 17331745.
  • 3
    Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS 2008; 22: 12471256.
  • 4
    Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27: 251259.
  • 5
    Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The MANIF 2000 Study Group. AIDS 2000; 14: 151155.
  • 6
    Stein MD, Rich JD, Maksad J et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse 2000; 26: 195205.
  • 7
    Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 2003; 32: 522526.
  • 8
    McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis 2005; 41 (Suppl. 1): S89S95.
  • 9
    Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002; 36: 15981613.
  • 10
    Strathdee SA, Palepu A, Cornelisse PG et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 547549.
  • 11
    Wood E, Hogg RS, Kerr T, Palepu A, Zhang R, Montaner JS. Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naïve HIV-infected injection drug users. AIDS 2005; 19: 837839.
  • 12
    Celentano DD, Galai N, Sethi AK et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001; 15: 17071715.
  • 13
    Murri R, Ammassari A, De Luca A, Cingolani A, Antinori A, Ortona L. Use of antiretroviral therapy by intravenous drug users with HIV. JAMA 1999; 281: 700701.
  • 14
    Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, Cleary PD. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med 2005; 165: 618623.
  • 15
    Wood E, Montaner JS. [Commentary] Antiretroviral therapy: a key part of the public health response to injection drug use. Addiction 2008; 103: 660661.
  • 16
    Sabin CA, Smith CJ, Youle M et al. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006; 20: 6771.
  • 17
    Sterne JA, Hernan MA, Ledergerber B et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366: 378384.
  • 18
    Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006; 163: 412420.
  • 19
    Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano DD. Longitudinal patterns of drug injection behavior in the ALIVE Study Cohort, 1988–2000: description and determinants. Am J Epidemiol 2003; 158: 695704.
  • 20
    Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353: 863868.
  • 21
    Glass TR, De Geest S, Weber R et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2006; 41: 385392.
  • 22
    Glass TR, De Geest S, Hirschel B et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther 2008; 13: 7785.
  • 23
    Weber R, Ledergerber B, Opravil M, Siegenthaler W, Luthy R. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. BMJ 1990; 301: 13621365.
  • 24
    Peterson PK, Gekker G, Chao CC, Schut R, Molitor TW, Balfour HH Jr. Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures. Involvement of transforming growth factor-beta. J Immunol 1991; 146: 8184.
  • 25
    Nair MP, Chadha KC, Hewitt RG, Mahajan S, Sweet A, Schwartz SA. Cocaine differentially modulates chemokine production by mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol 2000; 7: 96100.
  • 26
    Kapadia F, Vlahov D, Donahoe RM, Friedland G. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis 2005; 41: 10271034.
  • 27
    Pellegrino T, Bayer BM. In vivo effects of cocaine on immune cell function. J Neuroimmunol 1998; 83: 139147.
  • 28
    Pellegrino TC, Dunn KL, Bayer BM. Mechanisms of cocaine-induced decreases in immune cell function. Int Immunopharmacol 2001; 1: 665675.
  • 29
    Novick DM, Ochshorn M, Kreek MJ. In vivo and in vitro studies of opiates and cellular immunity in narcotic addicts. Adv Exp Med Biol 1991; 288: 159170.
  • 30
    Madden JJ, Wang Y, Lankford-Turner P, Donahoe RM. Does reduced DNA repair capacity play a role in HIV infection and progression in the lymphocytes of opiate addicts? J Acquir Immune Defic Syndr 2002; 31 (Suppl. 2): S78S83.
  • 31
    Ferreros I, Lumbreras B, Hurtado I, Perez-Hoyos S, Hernandez-Aguado I. The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users. Addiction 2008; 103: 651659.
  • 32
    Muga R, Langohr K, Tor J et al. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs. Clin Infect Dis 2007; 45: 370376.
  • 33
    Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15: 11151123.
  • 34
    FOPH. Swiss Federal Office for Public Health: Federal measures to reduce the problems of drug abuse. FOPH basic document 341f, Bern 1991.
  • 35
    Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001; 358: 14171423.
  • 36
    Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 2004; 35: 4651.
  • 37
    Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16: 767774.
  • 38
    Ledergerber B, Egger M, Rickenbach M, Weber R. Poverty and prognosis of HIV infection in Switzerland. Swiss HIV Cohort Study. AIDS 1998; 12: 19331934.
  • 39
    Simoni JM, Frick PA, Huang B. A longitudinal evaluation of a social support model of medication adherence among HIV-positive men and women on antiretroviral therapy. Health Psychol 2006; 25: 7481.
  • 40
    Ickovics JR, Hamburger ME, Vlahov D et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001; 285: 14661474.
  • 41
    Bouhnik AD, Preau M, Vincent E et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther 2005; 10: 5361.
  • 42
    Sorensen HJ, Jepsen PW, Haastrup S, Juel K. Drug-use pattern, comorbid psychosis and mortality in people with a history of opioid addiction. Acta Psychiatr Scand 2005; 111: 244249.
  • 43
    Lloyd-Smith E, Brodkin E, Wood E et al. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 2006; 20: 445450.
  • 44
    Copeland L, Budd J, Robertson JR, Elton RA. Changing patterns in causes of death in a cohort of injecting drug users, 1980–2001. Arch Intern Med 2004; 164: 12141220.
  • 45
    Ewings FM, Bhaskaran K, McLean K et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS 2008; 22: 8995.
  • 46
    Lucas GM, Weidle PJ, Hader S, Moore RD. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin Infect Dis 2004; 38 (Suppl. 5): S409S413.
  • 47
    Palepu A, Tyndall MW, Joy R et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84: 188194.
  • 48
    Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis 2007; 45: 770778.
  • 49
    Dronda F, Zamora J, Moreno S et al. CD4 cell recovery during successful antiretroviral therapy in naïve HIV-infected patients: the role of intravenous drug use. AIDS 2004; 18: 22102212.
  • 50
    Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 18001805.
  • 51
    Cofrancesco J Jr, Scherzer R, Tien PC et al. Illicit drug use and HIV treatment outcomes in a US cohort. AIDS 2008; 22: 357365.
  • 52
    Bale RN, Van Stone WW, Engelsing TM, Zarcone VP Jr, Kuldan JM. The validity of self-reported heroin use. Int J Addict 1981; 16: 13871398.
  • 53
    Dobler-Mikola A, Hattenschwiler J, Meili D, Beck T, Boni E, Modestin J. Patterns of heroin, cocaine, and alcohol abuse during long-term methadone maintenance treatment. J Subst Abuse Treat 2005; 29: 259265.
  • 54
    Jaggy C, Von Overbeck J, Ledergerber B et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362: 877878.
  • 55
    McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284: 16891695.
  • 56
    Smit C, Lindenburg K, Geskus RB, Brinkman K, Coutinho RA, Prins M. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour. Addiction 2006; 101: 433440.